If you allow us to, we use cookies to see how this website is used so that we can make it better. Learn about cookies

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Oral Health Management of Patients Prescribed Anti-resorptive or Anti-angiogenic Drugs – Consultation closes shortly

Posted by: Gregor Preston - Posted on:

SDCEP logo

The consultation period on new guidance from SDCEP on  the Oral Health Management of Patients Prescribed Anti-resorptive or Anti-angiogenic closes on the 1st October 2016.

This draft guidance is an update to the 2011 SDCEP publication Oral Health Management of Patients Prescribed Bisphosphonates and includes new advice on the wider range of drugs implicated in medication-related osteonecrosis of the jaw (MRONJ).

SDCEP would greatly appreciate your comments to help inform further development of this guidance before publication.

  • Electronic files of both the draft guidance and a feedback form can be obtained via the SDCEP website:
  • Feedback can also be submitted online via Questback.
  • Feedback closes on 1st October 2016.

The guidance is primarily intended for dentists in primary care dental practice, and will also be of relevance to the secondary care dental service, those involved in dental education, undergraduate trainees, prescribers of these drugs and patients.